A recent Dermatology digest,
as sent to subscribers

Study Type: Likely a case report/case series (dermoscopy image finding), based on title and journal format — cannot confirm without abstract text.

Key Question: Not stated; presumed focus is the diagnostic value of corkscrew and comma hairs on dermoscopy for tinea capitis.

Key Findings: Insufficient data provided in the abstract to extract specific findings, numbers, or outcomes.

Clinical Relevance: If confirmed, trichoscopic recognition of corkscrew/comma hairs could aid UK dermatologists and GPs in rapid, non-invasive diagnosis of tinea capitis, reducing reliance on mycology culture turnaround times within NHS pathways.

Limitations: No abstract text was available to assess study design, sample size, or evidence quality.

Study Type: No abstract text provided, so study design cannot be confirmed; title/context suggest a case series or retrospective cohort study.

Key Question: Not determinable from the available abstract—likely addresses the clinical, histopathological, and prognostic features of mycosis fungoides expressing a γδ T-cell immunophenotype.

Key Findings: No data provided to summarise; abstract content is missing.

Clinical Relevance: γδ T-cell phenotype in mycosis fungoides is clinically important as it may be associated with atypical presentations and historically poorer prognosis, information relevant to UK dermatologists and haemato-oncology MDTs managing cutaneous lymphomas.

Limitations: No abstract data available to assess methodology, sample size, or generalisability.

Study Type: Not determinable from available information — title format ("clinicopathologic challenge"–style case presentation) suggests this is likely a case report/case-based clinical quiz in JAMA Dermatology.

Key Question: Not stated; likely addresses the differential diagnosis and diagnostic work-up of annular, erosive plaques on the trunk in a male patient.

Key Findings: No data provided in the abstract to summarise.

Clinical Relevance: Case reports of unusual annular/erosive dermatoses are educationally useful for UK dermatologists in recognising atypical presentations that may mimic more common conditions (e.g., tinea, lupus, pemphigus variants).

Limitations: No abstract text was supplied, so critical appraisal is not possible.

Study Type: Retrospective cohort/database analysis (population-based prevalence study)

Key Question: What is the prevalence of vulvar lichen sclerosus among females, and how does it vary across age groups?

Key Findings:

• No numerical data provided in the supplied abstract—specific prevalence estimates, confidence intervals, and age-stratified rates are not available for extraction.
• The study appears designed to quantify disease burden across the female lifespan, likely using a large administrative or electronic health record dataset.

Clinical Relevance: Accurate prevalence data on vulvar lichen sclerosus would help UK dermatology and gynaecology services anticipate service demand, support earlier recognition (reducing risk of scarring and vulvar squamous cell carcinoma), and inform NHS resource allocation for chronic vulval disease clinics.

Limitations: The abstract text provided contains no methodological or numerical detail, precluding critical appraisal of study design, data source, or findings.

Study Type: Cross-sectional survey study (Delphi-derived instrument)

Key Question: How does access to dermatological care and workforce distribution vary globally across income levels and WHO regions?

Key Findings:

• Global dermatologist density averaged 2.66/100,000, ranging from 0.37 in low-income countries to 5.05 in high-income countries; estimated 175,633 dermatologists worldwide.
• Only 17% of countries met the estimated sufficiency threshold (5.63/100,000); 21% lacked any dermatology training programme; 42% reported inadequate/poor access overall.
• Dermatologists were heavily urban-concentrated (mean 79%), with worse maldistribution and subspecialty access (paediatric, surgical, dermatopathology) in lower-income settings; primary care physicians and non-physician workers substantially supplement dermatological care delivery.

Clinical Relevance: Highlights stark global inequities in dermatology workforce and training relevant to UK clinicians engaged in international health partnerships, global health electives, or workforce planning/advocacy through bodies like the British Association of Dermatologists.

Limitations: Findings rely on self-reported, expert-perception data (only 64% informed by objective data sources), introducing potential subjectivity and variable data quality across countries.

Study Type: Secondary analysis of a phase 3 RCT (VALOR trial)

Key Question: Does brepocitinib improve skin disease activity, itch, and quality of life in adults with dermatomyositis over 52 weeks?

Key Findings:

• Brepocitinib 30 mg outperformed placebo from week 4: CDASI-A change -6.4 vs -3.5 (difference -3.0; 95% CI -4.6 to -1.4); clinically meaningful CDASI-A response in 33.3% vs 17.7%.
• Itch remission (PP-NRS ≤1) achieved in 38.3% vs 19.0%; Skindex-16 improved by -12.9 vs -0.9 points.
• Among moderate-severe skin disease at baseline, higher clear/almost-clear rates (45.7% vs 21.8%) and functional skin remission (43.5% vs 20.8%) at week 52; safety consistent with class effects.

Clinical Relevance: Offers a potential oral, rapidly-acting therapy for refractory cutaneous dermatomyositis, an area of significant unmet need within NHS dermatology and rheumatology-dermatology joint clinics.

Limitations: As a secondary/exploratory analysis, findings require confirmation as primary endpoints and longer-term real-world safety data before UK licensing/adoption.

Study Type: Retrospective validation cohort study

Key Question: Does integrating clinicopathologic risk factors with 40-GEP testing (i40-GEP) improve risk stratification and guide adjuvant radiotherapy decisions in high-risk cutaneous SCC?

Key Findings:

• i40-GEP significantly stratified metastatic and local recurrence risk (p<0.001, n=572), with Class 1A showing >95% NPV across NCCN risk subsets.
• Class 2B (12.9% of cohort) had the lowest 3-year metastasis-free survival (66.2%) and showed demonstrable benefit from adjuvant radiation therapy.
• On multivariable analysis, i40-GEP outperformed individual clinicopathologic factors in predicting metastasis and recurrence.

Clinical Relevance: For UK dermatology and skin cancer MDTs managing HRcSCC, i40-GEP could help identify patients most likely to benefit from adjuvant radiotherapy, potentially reducing over- and under-treatment within NHS pathways.

Limitations: Retrospective design limits causal inference regarding radiotherapy benefit.

Study Type: Narrative clinical review

Key Question: How should treatment selection for pyoderma gangrenosum (PG) be tailored according to associated systemic comorbidities?

Key Findings:

• Comorbidity-directed biologic/small-molecule therapy (e.g., TNF inhibitors for IBD-associated PG, IL-1 blockade for autoinflammatory syndromes, JAK inhibitors for arthritis-overlap PG) was associated with higher healing rates and lower relapse than empiric treatment.
• Evidence is drawn from case series and real-world reports rather than comparative trials, so no pooled effect sizes are reported.
• Individualised, mechanism-based therapy targeting underlying systemic drivers appears to produce more durable ulcer healing.

Clinical Relevance: Offers UK dermatologists a practical framework for selecting biologics/JAK inhibitors based on PG comorbidity profile, relevant given increasing biologic access via NHS specialist commissioning pathways.

Limitations: Based on heterogeneous, largely uncontrolled case-level evidence, limiting strength of causal or comparative conclusions.